The U.S. Cybersecurity and Infrastructure Security Agency (CISA) and Food and Drug Administration (FDA) have issued an advisory about critical security vulnerabilities in Illumina’s next-generation sequencing (NGS) software.
Three of the flaws are rated 10 out of 10 for severity on the Common Vulnerability Scoring System (CVSS), with two others having severity ratings of 9.1 and 7.4.
The issues impact software in medical devices used for “clinical diagnostic use in sequencing a person’s DNA or testing for various genetic conditions, or for research use only,” according to the FDA.
